Clinical trials: Peritoneal Cancer
Ovarian Cancer, Peritoneal Neoplasms
BOVARI: A Non-Interventional Study of Avastin (Bevacizumab) as Front-Line Treatment in Patients With Ovarian Cancer
This non-interventional study will evaluate the routine use and the safety and efficacy of Avastin (bevacizumab) as first-line treatment in patients with advanced ovarian cancer (epithelial ovarian cancer, fallopian tube…
- Trial name
- NCT01788995
- Where
- Austria
- Volunteers
- 63 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer, Peritoneal Metastases
ctDNA as a Assisted Diagnosis, Early Intervention and Prognostic Marker for Peritoneal Metastases From Colorectal Cancer
This is a prospective, open-label, randomized controlled clinical trial, by monitoring the serum ctDNA mutational profile using NGS, aiming to elucidate the correlation between the postoperative ctDNA status and the assisted…
- Trial name
- NCT04752930
- Testing
- ctDNA monitoring, Imageology
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Advanced Ovarian Cancer
Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin
Impact of the combination of Olaparib and Pegylated Liposomal Doxorubicin on improvement of progression-free survival at 6 months in patients with platinum resistant advanced ovarian cancer.
- Trial name
- ROLANDO (NCT03161132)
- Testing
- Olaparib, Pegylated Liposomal Doxorubicin
- Where
- 8 sites in Spain
- Volunteers
- 32 people
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
This phase II trial tests whether pembrolizumab combined with bevacizumab with or without agonist anti-CD40 CDX-1140 works to shrink tumors in patients with ovarian cancer that has come back (recurrent).
- Conditions
- Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT05231122
- Testing
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Roswell Park Cancer Institute
Anastomotic Leak, Colorectal Cancer
The Prediction of Anastomotic Insufficiency Risk After Colorectal Surgery (PANIC) Study
The Prediction of Anastomotic Insufficiency risk after Colorectal surgery (PANIC) study aims to establish a machine-learning-based application that allows for accurate preoperative prediction of patients at risk for anastomotic…
- Conditions
- Anastomotic Leak, Colorectal Cancer, Diverticulosis, Crohn Disease
- Trial name
- NCT04985981
- Where
- 2 sites in Switzerland
- Volunteers
- 11,000 people
- Sponsor
- Michel Adamina, MD
Fallopian Tube Endometrioid Tumor, Fallopian Tube Mucinous Neoplasm
Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase II trial studies how well physical activity monitored by Fitbit Charge 2 works in improving quality of life in participants with ovarian, primary peritoneal, or fallopian tube cancer that has come back.
- Conditions
- Fallopian Tube Endometrioid Tumor, Fallopian Tube Mucinous Neoplasm, Fallopian Tube Serous Neoplasm, Ovarian Clear Cell Tumor
- Trial name
- NCT03685695
- Testing
- Laboratory Biomarker Analysis, Monitoring Device, Physical Activity
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Roswell Park Cancer Institute
Gastric Cancer (GC), Pancreatic Cancer
Prediction of Peritoneal Dissemination of Digestive Tumors Through the Study of Circulating Tumor DNA
The peritoneum is a relatively frequent metastatic site in digestive tumors (colon, stomach, pancreas) and is characterized by a poorer prognosis compared with other metastatic sites such as the lung or liver.
- Conditions
- Gastric Cancer (GC), Pancreatic Cancer, Colorectal Cancer
- Trial name
- PREDIPER (NCT07574957)
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Fallopian Tube Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma
First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
This phase II trial studies how well first-line treatment of bevacizumab, carboplatin, and paclitaxel work in treating participants with stage III- IV ovarian, primary peritoneal and fallopian tube cancer.
- Conditions
- Fallopian Tube Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma
- Trial name
- NCT01097746
- Testing
- Bevacizumab, Carboplatin, Paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer, Fallopian Tube Cancer
Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma
In this study, patients with relapsed or refractory ovarian cancer will receive treatment with pazopanib and liposomal doxorubicin (Doxil) until disease progression or unacceptable toxicity occurs.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma
- Trial name
- NCT01035658
- Testing
- Pazopanib, Doxil
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- SCRI Development Innovations, LLC
Ovarian Cancer, Peritoneal Cavity Cancer
Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer
RATIONALE: Giving colony-stimulating factors, such as G-CSF help stem cells move from the patient's bone marrow to the blood so they can be collected and stored.
- Trial name
- NCT00652691
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Volunteers
- 48 people
- Sponsor
- Mayo Clinic
Ovarian Cancer
A Study of SHR-A1811 in Subjects With Ovarian Cancer
This is an open-label study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with ovarian cancer.
- Trial name
- NCT06828354
- Testing
- SHR-A1811, Paclitaxel Injection, Doxorubicin Hydrochloride Liposome Injection
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Ovarian Cancer, Fallopian Tube Cancer
Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer
Phase I study to evaluate intraperitoneal carboplatin along with weekly intravenous paclitaxel and bevacizumab in order to establish a tolerable dose and define the toxicity of this regimen in previously untreated patients with…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, No Prior Chemotherapy
- Trial name
- NCT01220154
- Testing
- Paclitaxel, Carboplatin, Bevacizumab
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- David O'Malley
Peritoneal Carcinomatosis, Gastric Cancer
Neo-adjuvant Chemo + Peritonectomy + Hyperthermic Intraperitoneal Chemo in Peritoneal Carcinomatosis From Gastric Cancer
The aims of this study are to investigate whether multimodal treatment of peritoneal carcinomatosis from gastric cancer is feasible and to evaluate the clinical outcomes and clinical effectiveness of neoadjuvant systemic…
- Trial name
- NCT01379482
- Testing
- Multimodal treatment
- Where
- Sweden
- Volunteers
- 18 people
- Sponsor
- Uppsala University
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
This phase I/II trial studies the side effects and best dose of oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS) infected mesenchymal stem cells and to see how well it works in treating patients with…
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma
- Trial name
- NCT02068794
- Testing
- Laboratory Biomarker Analysis, Mesenchymal Stem Cell Transplantation, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Mayo Clinic
Anal Cancer, Carcinoma of the Appendix
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
RATIONALE: Palonosetron hydrochloride may prevent nausea and vomiting caused by radiation therapy. It is not yet known whether palonosetron hydrochloride is more effective than a placebo in preventing nausea and vomiting.
- Conditions
- Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer, Extrahepatic Bile Duct Cancer
- Trial name
- NCT00903396
- Testing
- palonosetron hydrochloride
- Where
- 69 sites in United States
- Volunteers
- 7 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Solid Tumors
Study of INCB123667 in Subjects With Advanced Solid Tumors
This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and in combination with…
- Trial name
- NCT05238922
- Testing
- INCB0123667, Palbociclib, Bevacizumab
- Where
- 41 sites in United States, France and 6 more
- Volunteers
- 291 people
- Sponsor
- Incyte Corporation
Peritoneal Carcinomatosis
Clinical Pharmacology of Platinum-based Hyperthermic Intraperitoneal Chemotherapy
Currently, there is a lack of knowledge on the effect of additional flushing after HIPEC on tumour platinum exposure, systemic platinum exposure and platinum concentration in drain exudate and thereby personal exposure.
- Trial name
- GUTOX (NCT03364907)
- Testing
- HIPEC with flushing afterwards, HIPEC without flushing afterwards
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Radboud University Medical Center
Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,, Primary Peritoneal Cancer or Endometrial Cancer
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
This study was a Phase 1 and pharmacologic open-labeled dose-escalation trial of MM-121 in combination with paclitaxel using a "3+3" design.
- Conditions
- Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,, Primary Peritoneal Cancer or Endometrial Cancer, Locally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer
- Trial name
- NCT01209195
- Testing
- MM-121, Paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 41 people
- Sponsor
- Merrimack Pharmaceuticals
Gastric Cancer, Peritoneal Metastases
Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
Peritoneal metastasis of gastric cancer is difficult to be detected in time, thus delaying treatment. Based on the conventional CT images of gastric cancer, this study plans to develop, improve and validate an intelligent…
- Trial name
- NCT05722275
- Testing
- Peritoneal metastasis status ascertainment
- Where
- 13 sites in China, Italy
- Volunteers
- 400 people
- Sponsor
- Chinese Academy of Sciences
Ovarian Cancer Stage IV, Peritoneal Cancer
Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer
This is a single arm feasibility study in patients with primary FIGO stage IV serous ovarian, peritoneal, or fallopian tube cancer to evaluate neo-adjuvant + adjuvant pembrolizumab for its capacity to induce and broaden T cell…
- Conditions
- Ovarian Cancer Stage IV, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT03126812
- Testing
- Carboplatin, Paclitaxel, Pembrolizumab
- Where
- Netherlands
- Volunteers
- 33 people
- Sponsor
- The Netherlands Cancer Institute